Effects of probiotics, prebiotics, and synbiotics on polycystic ovary syndrome: a systematic review and meta-analysis

被引:32
作者
Li, Yuling [1 ,2 ]
Tan, Yong [1 ,2 ]
Xia, Guicheng [1 ,2 ]
Shuai, Jiaqi [3 ]
机构
[1] Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing, Peoples R China
[2] Nanjing Univ Chinese Med, Nanjing, Peoples R China
[3] Masaryk Univ, Brno, Czech Republic
基金
中国国家自然科学基金;
关键词
Meta-analysis; polycystic ovary syndrome synbiotic; prebiotic; probiotic; REVISED; 2003; CONSENSUS; WEIGHT-LOSS; DOUBLE-BLIND; GUT MICROBIOTA; DIAGNOSTIC-CRITERIA; GLYCEMIC CONTROL; SUPPLEMENTATION; HEALTH; WOMEN; INFLAMMATION;
D O I
10.1080/10408398.2021.1951155
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effects of probiotics, prebiotics, and synbiotics on insulin resistance (IR), lipid profiles, anthropometric indices, and C-reactive protein (CRP) level for polycystic ovary syndrome (PCOS). We searched 8 databases from their inception until 1st October, 2020. The effect sizes were expressed as standardized mean difference (SMD) with 95% confidence intervals (95% CI). Subgroup analyses were undertaken for further identification of effects of probiotics, prebiotics, and synbiotics, based on the following aspects: (1) type of intervention (probiotics, prebiotics, or synbiotics); (2) study duration (>= 12 weeks or < 12 weeks); (3) number of probiotic strains (multi strains or single strain); (4) probiotic dose (>= 2 x 10(8) colony-forming units [CFU] or < 2 x 10(8) CFU). A total of 17 eligible RCTs with 1049 participants were included. Results showed that probiotic, prebiotic, and synbiotic intake decreased fasting plasma glucose (SMD, -1.35; 95% CI, -2.22 to -0.49; p = 0.002), fasting insulin (SMD, -0.68; 95% CI, -1.08 to -0.27; p = 0.001), homeostatic model of assessment for IR (SMD, -0.73; 95% CI, -1.15 to -0.31; p = 0.001), triglycerides (SMD, -0.85; 95% CI, -1.59 to -0.11; p = 0.024), total cholesterol (SMD, -1.09; 95% CI, -1.98 to -0.21; p = 0.015), low-density lipoprotein cholesterol (SMD, -0.84; 95% CI, -1.64 to -0.03; p = 0.041), very-low-density lipoprotein cholesterol (SMD, -0.44; 95% CI, -0.70 to -0.18; p = 0.001), and increased quantitative insulin sensitivity check index (SMD, 2.00; 95% CI, - 0.79 to 3.22; p = 0.001). However, probiotic, prebiotic, and synbiotic supplements did not affect anthropometric indices, high-density lipoprotein cholesterol, and CRP levels. Subgroup analysis showed that probiotic or prebiotic might be the optimal choice for ameliorating IR or lipid profiles, respectively. Additionally, the effect was positively related to courses and therapeutical dose. Overall, the meta-analysis demonstrates that probiotic, prebiotic, or synbiotic administration is an effective and safe intervention for modifying IR and lipid profiles.
引用
收藏
页码:522 / 538
页数:17
相关论文
共 83 条
[41]   Effectiveness of probiotics in type 2 diabetes: a meta-analysis [J].
Kasinska, Marta A. ;
Drzewoski, Jozef .
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2015, 125 (11) :803-813
[42]   Regulation of intestinal lipid metabolism: current concepts and relevance to disease [J].
Ko, Chih-Wei ;
Qu, Jie ;
Black, Dennis D. ;
Tso, Patrick .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (03) :169-183
[43]   The effects of aerobic physical exercises on body image among women with polycystic ovary syndrome [J].
Kogure, Gislaine Satyko ;
Lopes, Iris Palma ;
Ribeiro, Victor Barbosa ;
Mendes, Maria Celia ;
Kodato, Sergio ;
Miranda Furtado, Cristiana Libardi ;
Silva de Sa, Marcos Felipe ;
Ferriani, Rui Alberto ;
da Silva Lara, Lucia Alves ;
dos Reis, Rosana Maria .
JOURNAL OF AFFECTIVE DISORDERS, 2020, 262 :350-358
[44]   Meta-analysis of the effects of probiotic supplementation on glycemia, lipidic profiles, weight loss and C-reactive protein in women with polycystic ovarian syndrome [J].
Liao, Dan ;
Zhong, Chunhua ;
Li, Cuifen ;
Mo, Lifang ;
Liu, Yanyan .
MINERVA MEDICA, 2018, 109 (06) :479-487
[45]   Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study [J].
Lindheim, Lisa ;
Bashir, Mina ;
Muenzker, Julia ;
Trummer, Christian ;
Zachhuber, Verena ;
Leber, Bettina ;
Horvath, Angela ;
Pieber, Thomas R. ;
Gorkiewicz, Gregor ;
Stadlbauer, Vanessa ;
Obermayer-Pietsch, Barbara .
PLOS ONE, 2017, 12 (01)
[46]   Dysbiosis of Gut Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome [J].
Liu, Rui ;
Zhang, Chenhong ;
Shi, Yu ;
Zhang, Feng ;
Li, Linxia ;
Wang, Xuejiao ;
Ling, Yunxia ;
Fu, Huaqing ;
Dong, Weiping ;
Shen, Jian ;
Reeves, Andrew ;
Greenberg, Andrew S. ;
Zhao, Liping ;
Peng, Yongde ;
Ding, Xiaoying .
FRONTIERS IN MICROBIOLOGY, 2017, 8
[47]   Insulin and the polycystic ovary syndrome [J].
Macut, Djuro ;
Bjekic-Macut, Jelica ;
Rahelic, Dario ;
Doknic, Mirjana .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 130 :163-170
[48]   Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity [J].
Meng, Xiang ;
Zhou, Hao-Yue ;
Shen, Hui-Hui ;
Lufumpa, Eniya ;
Li, Xiao-Mei ;
Guo, Biao ;
Li, Bao-Zhu .
AUTOIMMUNITY REVIEWS, 2019, 18 (05) :455-475
[49]   Insulin Resistance and Polycystic Ovary Syndrome [J].
Moghetti, Paolo .
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (36) :5526-5534
[50]   The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial (Publication with Expression of Concern) [J].
Nasri, Khadijeh ;
Jamilian, Mehri ;
Rahmani, Elham ;
Bahmani, Fereshteh ;
Tajabadi-Ebrahimi, Maryam ;
Asemi, Zatollah .
BMC ENDOCRINE DISORDERS, 2018, 18